Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 5NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Thoracic 3Myeloid 3Other solid neoplasm 2Head & Neck 2Genitourinary 2Classical hematology 2Sarcoma 1Plasma cell 1Other neoplasm 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Amifostine × Genitourinary × Clear all
NCT00217542 2013-05-03

Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
42 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT00040365 2012-04-30

Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
30 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡